The good news, said Dr. Eidelberg, is that the grafts stayed where they were and delivered dopamine to the tissue. The finding is critical as the field moves to transplant other types of cells, including embryonic stem cells or their ultimate product.
Much of the work for this study was conducted by Feinstein scientist Yilong Ma, MD, in collaboration with Dr. Eidelberg. The fetal cell transplant study was conducted by Paul Greene, MD, and Stanley Fahn, MD, Department of Neurology, Columbia College of Physicians and Surgeons, New York, New York and Robert Breeze, MD, Department of Neurosurgery, University of Colorado School of Medicine, Denver, Colorado; and Curt Freed, MD, Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado School of Medicine, Denver, Colorado.
About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research (www.feinsteininstitute.org) is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson's disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.
Contact: Jamie Talan, science writer-in-residence,
516-562-1232 or email JTalan3k(at)aol(dot)com
# # #
Read the full story at http://www.prweb.com/releases/Fetal_Transplant_Surgery/Parkinsons_Disease/prweb3388034.htm.
Copyright©2009 Vocus, Inc.
All rights reserved